Recent Posts
- NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
- Nordic Group B.V. Through its Subsidiary Nordic Pharma, Inc. (U.S.), Announces LACRIFILL® Canalicular Gel Inclusion in New Dry Eye Workshop (DEWS) III Management and Therapy Report From The Tear Film and Ocular Surface Society (TFOS) in American Journal of Ophthalmology
- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces launch of authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
- Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Presenting Patient Data and Patient Experience Study for LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
- Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Details of LACRIFILL® Canalicular Gel Poster Presentation At SECO 2025
Archives
- October 2025
- August 2025
- April 2025
- March 2025
- October 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- June 2023
- July 2022
- June 2022
- February 2022
- December 2021
- November 2021
- October 2021
- August 2021
- March 2021
- December 2020
- August 2020
- June 2019
- January 2019
- July 2018
- June 2017
- March 2017
- April 2016
- March 2016
- January 2016
- December 2015
- June 2015
Recent Comments